New hope for older AML patients: Four-Drug combo trial launches
NCT ID NCT06532552
First seen Nov 19, 2025 · Last updated May 16, 2026 · Updated 18 times
Summary
This study compares four different drug combinations for adults newly diagnosed with acute myeloid leukemia (AML) who cannot tolerate or choose not to have intensive chemotherapy. The combinations include venetoclax and azacitidine (VA) alone or with either cladribine, chidamide, or alternating between the two. The goal is to see which combination works best to control the disease and prevent relapse. About 172 participants will be randomly assigned to one of the four groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEWLY DIAGNOSED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.